

SCIENTIFIC PROGRAM

THURSDAY, SEPTEMBER 18, 2008

08.30-10.00		Opening Session	Room 517
		<p>Plenary Session 1 Co-Chairs: Jack Antel (Montréal, Québec, Canada) and Jerry Wolinsky (Houston, Texas, USA)</p> <p>Welcoming Remarks On behalf of ACTRIMS,ECTRIMS and LACTRIMS Jerry Wolinsky (Houston, Texas, USA)</p> <p>On behalf of MS Societies Joyce Nelson, National Multiple Sclerosis Society Yves Savoie, Multiple Sclerosis Society of Canada</p> <p>On behalf of the Local Organizing Committee François Grand'Maison (Montreal, Quebec, Canada)</p> <p>On behalf of people affected by MS Arlette Cousture, Author</p> <p>ACTRIMS/CMSC+ Donald Paty Memorial Lecture Introduction: Pierre Duquette (Montréal, Québec, Canada)</p> <p>12* The changing frame of MS over the centuries T. Jock Murray (Halifax, Nova Scotia, Canada) + <i>The Consortium of Multiple Sclerosis Centers</i></p>	
10.00-10.30		Coffee Break	Room 220D
10.30-12.00		Parallel Session 1	Room 517A
		<p>Neurodegeneration and Inflammation: Which Comes First? Co-Chairs: Cedric Raine (Bronx, New York, USA) and Frauke Zipp (Berlin, Germany)</p> <p>10.30 13* Evidence for primary neurodegeneration in MS Wolfgang Brück (Göttingen, Germany)</p> <p>10.50 14* Evidence for secondary neurodegeneration in MS Wayne Moore (Vancouver, British Columbia, Canada)</p> <p>11.10 15 Homogeneity of active demyelinating lesions in patients with established multiple sclerosis Esther Breij (Amsterdam, Netherlands)</p> <p>11.25 16 The progression of brain atrophy is similar in drug-free MS subtypes: a longitudinal study of a large patient population Antonio Giorgio (Sienna, Italy)</p> <p>11.40 17 Treatment with glatiramer acetate protects axons in patients with clinically isolated syndromes: evidence from the PreCISe trial Douglas Arnold (Montréal, Québec, Canada)</p>	
10.30-12.00		Parallel Session 2	Room 517D
		<p>Neuromyelitis Optica (NMO) Co-Chairs: Gavin Giovannoni (London, United Kingdom) and Claudia Lucchinetti (Rochester, Minnesota, USA)</p> <p>10.30 18* Clinical pathological spectrum of NMO Hans Lassman (Vienna, Austria)</p> <p>10.50 19* Clinical features of NMO in Latin American populations Marco Lana-Peixoto (Belo Horizonte, Brazil)</p> <p>11.10 20* Treatments for NMO Dean Wingerchuk (Scottsdale, Arizona, USA)</p> <p>11.30 21 Effects of B cell depletion on T cell subsets and function in neuromyelitis optica Claude Genain (San Francisco, California, USA)</p> <p>11.45 22 Evaluation of different techniques to detect anti-aquaporin 4 antibodies in neuromyelitis optica patients Roberto Furlan (Milan, Italy)</p>	

* Invited lectures

SCIENTIFIC PROGRAM

THURSDAY, SEPTEMBER 18, 2008 (CONT.)

12.00-14.00		Lunch and Poster Viewing	Room 220D
12.45-13.45		Sponsored Satellite Symposium – Teva & sanofi-aventis	Room 517A
		<p>Improving the Course of MS: Treat Today for a Better Tomorrow Co-Chairs: Douglas Arnold (Montréal, Québec, Canada) and Paul O'Connor (Toronto, Ontario, Canada)</p> <p>Early treatment: PreCISe-ly what the patients need Giancarlo Comi (Milan, Italy)</p> <p>Immunomodulation and neuroprotection: MRI perspectives Robert Zivadinov (Buffalo, New York, USA)</p> <p>Immunomodulation and neuroprotection: long term perspective Xavier Montalban (Barcelona, Spain)</p> <p>Questions and Conclusion</p>	
14.00-15.30		Parallel Session 3	Room 517A
		<p>Brain Plasticity and Repair Co-Chairs: Tomas Olsson (Stockholm, Sweden) and Krzysztof Selmaj (Lodz, Poland)</p>	
14.00	23*	Myelin repair in the central nervous system: role of guidance molecules Catherine Lubetzki (Paris, France)	
14.20	24*	Axo-glial interactions: role of transporters and glutamate receptors Peter Stys (Ottawa, Ontario, Canada)	
14.40	25*	New observations on the mechanism of myelin wrapping David Colman (Montréal, Québec, Canada)	
15.00	26	Roles of Sirt1 for redox-dependent fate of neural progenitors in the course of chronic autoimmune neuroinflammation Orhan Aktas (Berlin, Germany)	
15.15	27	Mesenchymal stem cells as treatment for multiple sclerosis: immunomodulation versus tissue repair Antonio Uccelli (Genoa, Italy)	
14.00-15.30		Parallel Session 4	Room 517D
		<p>Antibodies: From Pathogenesis to Treatment Co-Chairs: Bernard Hemmer (Munich, Germany) and Robert Naismith (St. Louis, Missouri, USA)</p>	
14.00	28*	What is the evidence in humans that auto-antibodies to CNS antigens are pathogenic? Jeffrey Bennett (Denver, Colorado, USA)	
14.20	29*	Monoclonal antibodies: the future Steve Hauser (San Francisco, California, USA)	
14.40	30	Lipids as autoantigens and therapeutic immune modulators in multiple sclerosis Peggy Ho (Stanford, California, USA)	
14.55	31	Alterations in cerebrospinal fluid chemokine pattern following B-cell depletion with rituximab in relapsing multiple sclerosis patients. Anne Cross (St. Louis, Missouri, USA)	
15.10	32	Molecular characterization of CSF B-cell response in multiple sclerosis Jerry Lin (New York, New York, USA)	
15.30-17.00		Poster Session 1 and Coffee Break	Room 220D
		Posters P1 – P450, with authors present	

SCIENTIFIC PROGRAM

THURSDAY, SEPTEMBER 18, 2008 (CONT.)

17:00-17:45		Hot Topic 1	Room 517A
		Costs and Availability of MS Treatments Co-Chairs: Marco Medina (Tegucigalpa, Honduras) and Carlos Oehninger (Montevideo, Uruguay)	
17:00	33*	The impact of generics and biosimilars in interferons Victor Rivera (Mexico City, Mexico)	
17:15	34*	Costs and availability of multiple sclerosis treatments: impact on social security and public health systems in Latin America Arnoldo Soto (Caracas, Venezuela)	
17:30	35	Autologous stem cell transplantation in multiple sclerosis Amilton Barreira (Sao Paulo, Brazil)	
17:00-17:45		Hot Topic 2	Room 517D
		Genomics and Proteomics in Understanding MS Co-Chairs: Reinhard Hohlfeld (Munich, Germany) and John Richert (New York, New York, USA)	
17:00	36*	Do different disease courses display specific genomic features? Jonathan Haines (Memphis, Tennessee, USA)	
17:15	37*	Proteomics and transcriptional profiling in understanding the pathogenesis of multiple sclerosis Lawrence Steinman (Stanford, California, USA)	
17:30	38	Altered microRNA expression in lymphocytes of relapsing-remitting multiple sclerosis patients Raija Lindberg (Basel, Switzerland)	
17:00-17:45		Hot Topic 3	Room 520
		Pediatric MS Co-Chairs: Eva Havrdova (Prague, Czech Republic) and Lauren Krupp (Stony Brook, New York, USA)	
17:00	39*	Clinical features of pediatric multiple sclerosis Sylvia Tenenbaum (Buenos Aires, Argentina)	
17:15	40*	Environmental influences and immunological features of multiple sclerosis in children Brenda Banwell (Toronto, Ontario, Canada)	
17:30	41	Encephalopathic presentation of central nervous system aquaporin-4 autoimmunity in childhood Nancy Kuntz (Rochester, Minnesota, USA)	
18:00-19:00		Sponsored Satellite Symposium – EMD Serono	Room 517A
		Improving MS Treatment: Building on the Past to Prepare for the Future Co-Chairs: Gavin Giovannoni (London, United Kingdom) and Anthony Traboulsee (Vancouver, British Columbia, Canada)	
18:00		Welcome	
18:05		A decade of experience with interferons in MS Mark Freedman (Toronto, Ontario, Canada)	
18:20		Interferons and cognition in MS Stephen Rao (Cleveland, Ohio, USA)	
18:35		Interferons in MS: a look to the future Bernd Kieseier (Düsseldorf, Germany)	
18:50		Questions and panel discussion	

* Invited lectures

SCIENTIFIC PROGRAM

THURSDAY, SEPTEMBER 18, 2008 (CONT.)

18.00-19.30	ECTRIMS Council meeting (by invitation only)	Room 516A
19.15-20.15	Sponsored Satellite Symposium – Biogen Idec and Elan	Room 517D
	<p>Taking on MS – Targeting Defined Pathways Chair: Paul O'Connor (Toronto, Ontario, Canada)</p> <p>Taking the 1st step in addressing the entire disability picture Heinz Wiendl (Wurzburg, Germany)</p> <p>Taking a step closer towards freedom from disease activity Howard Rossman (Farmington Hills, Michigan, USA)</p>	

EVALUATE THE WORLD CONGRESS SCIENTIFIC PROGRAM AND
CLAIM YOUR CME CERTIFICATE ONLINE WWW.MSMONTREAL.ORG

FRIDAY, SEPTEMBER 19, 2008

7.45-8.45	Sponsored Satellite Symposium – Novartis	Room 517
	<p>Oral Fingolimod: From Innovative Science to Clinical Promise Co-Chairs: Chris Polman (Amsterdam, Netherlands) and Jack Antel (Montréal, Québec, Canada)</p>	
07.45	Welcome and Introduction Chris Polman	
07.50	What we have learned from Phase II and III studies in RRMS Ludwig Kappos (Basel, Switzerland)	
08.05	Sphingosine-1-phosphate (S1P) receptor modulation: effects on the immune and central nervous system Jerold Chun (San Diego, California, USA)	
08.25	Oral fingolimod: Phase III in PPMS Alan Thompson (London, United Kingdom)	
08.35	Questions and answers/Closing remarks	
09.00-10.00	Plenary Session 2	Room 517
	<p>Co-Chairs: Jack Antel (Montréal, Québec, Canada) and Hans-Peter Hartung (Düsseldorf, Germany)</p> <p>ECTRIMS Lecture What Can we Learn from Treating Multiple Sclerosis? Chris Polman (Amsterdam, Netherlands)</p>	
10.00-10.30	Coffee Break and Poster Viewing	Room 220D